Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III: APR 246 PLUS AZACITIDINE (AZA) IN TP53 MUTATED (M) MDS AND AML. LONG TERM FOLLOW UP OF PHASE 2 STUDY BY THE GFM. (September 2021) - Cluzeau, T.; Sebert, M.; Rahmé, R.; Cuzzubbo, S.; Walter-Petrich, A.; Peterlin, P.; Recher, C.; Stamatoullas, A.; Willems, L.; Raffoux, E.; Berthon, C.; Sallman, D.; et al.